OBJECTIVE: To determine visceral adiposity (VAT), subcutaneous adiposity (SAT), and regional body adipose differences between HIV-infected and non-HIV-infected subjects in relation to body mass index (BMI) and World Health Organization BMI categories. DESIGN, SETTING, AND PARTICIPANTS: Analyses were conducted of 306 HIV-infected and 107 community-derived HIV-negative subjects evaluated for metabolic studies between 1999 and 2006. Analyses were stratified by gender. Additional analyses were performed stratifying subjects by metabolic syndrome status. RESULTS: HIV-infected men and women demonstrated decreased total extremity fat by 1.1 kg and 0.85 kg, respectively, relative to non-HIV-infected control subjects. VAT was increased among HIV-infected men and women in the normal (18.5 to 24.9 kg/m2) and overweight (25.0 to 29.9 kg/m2) categories relative to control subjects but not among those in the obese category (> or =30.0 kg/m2). In contrast, abdominal SAT was reduced among HIV-infected men in the normal and overweight categories but was similar among HIV-infected women and control subjects in these categories. Abdominal SAT was increased among HIV-infected women in the obese category relative to control subjects. Similar results were obtained limiting the analysis to HIV-infected (n = 204) and control subjects (n = 89) without the metabolic syndrome. CONCLUSIONS: Peripheral lipoatrophy is a consistent finding among HIV-infected men and women with metabolic abnormalities. Relative increases in VAT are most pronounced among male and female HIV-infected subjects in the normal weight and overweight categories. Gender differences in abdominal SAT accumulation are observed, with preservation of SAT among HIV-infected women relative to control subjects.
OBJECTIVE: To determine visceral adiposity (VAT), subcutaneous adiposity (SAT), and regional body adipose differences between HIV-infected and non-HIV-infected subjects in relation to body mass index (BMI) and World Health Organization BMI categories. DESIGN, SETTING, AND PARTICIPANTS: Analyses were conducted of 306 HIV-infected and 107 community-derived HIV-negative subjects evaluated for metabolic studies between 1999 and 2006. Analyses were stratified by gender. Additional analyses were performed stratifying subjects by metabolic syndrome status. RESULTS:HIV-infectedmen and women demonstrated decreased total extremity fat by 1.1 kg and 0.85 kg, respectively, relative to non-HIV-infected control subjects. VAT was increased among HIV-infectedmen and women in the normal (18.5 to 24.9 kg/m2) and overweight (25.0 to 29.9 kg/m2) categories relative to control subjects but not among those in the obese category (> or =30.0 kg/m2). In contrast, abdominal SAT was reduced among HIV-infectedmen in the normal and overweight categories but was similar among HIV-infectedwomen and control subjects in these categories. Abdominal SAT was increased among HIV-infectedwomen in the obese category relative to control subjects. Similar results were obtained limiting the analysis to HIV-infected (n = 204) and control subjects (n = 89) without the metabolic syndrome. CONCLUSIONS: Peripheral lipoatrophy is a consistent finding among HIV-infectedmen and women with metabolic abnormalities. Relative increases in VAT are most pronounced among male and female HIV-infected subjects in the normal weight and overweight categories. Gender differences in abdominal SAT accumulation are observed, with preservation of SAT among HIV-infectedwomen relative to control subjects.
Authors: T Saint-Marc; M Partisani; I Poizot-Martin; F Bruno; O Rouviere; J M Lang; J A Gastaut; J L Touraine Journal: AIDS Date: 1999-09-10 Impact factor: 4.177
Authors: Sara E Dolan; Walter Frontera; Jamie Librizzi; Karin Ljungquist; Sandra Juan; Robert Dorman; Morgan E Cole; Jenna R Kanter; Steven Grinspoon Journal: Arch Intern Med Date: 2006-06-12
Authors: C Hadigan; D Kamin; J Liebau; S Mazza; S Barrow; M Torriani; R Rubin; S Weise; A Fischman; S Grinspoon Journal: Am J Physiol Endocrinol Metab Date: 2005-08-30 Impact factor: 4.310
Authors: C Gervasoni; A L Ridolfo; G Trifirò; S Santambrogio; G Norbiato; M Musicco; M Clerici; M Galli; M Moroni Journal: AIDS Date: 1999-03-11 Impact factor: 4.177
Authors: J A Suwaidi; R S Wright; J P Grill; D D Hensrud; J G Murphy; R W Squires; S L Kopecky Journal: Clin Cardiol Date: 2001-08 Impact factor: 2.882
Authors: Rebecca P Gelber; J Michael Gaziano; JoAnn E Manson; Julie E Buring; Howard D Sesso Journal: Am J Hypertens Date: 2007-04 Impact factor: 2.689
Authors: Phyllis C Tien; Stephen R Cole; Carolyn Masters Williams; Rui Li; Jessica E Justman; Mardge H Cohen; Mary Young; Nancy Rubin; Michael Augenbraun; Carl Grunfeld Journal: J Acquir Immune Defic Syndr Date: 2003-12-15 Impact factor: 3.731
Authors: Jordan E Lake; Mikhail Popov; Wendy S Post; Frank J Palella; Ned Sacktor; Eric N Miller; Todd T Brown; James T Becker Journal: J Neurovirol Date: 2016-12-15 Impact factor: 2.643
Authors: Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn Journal: Expert Rev Clin Pharmacol Date: 2019-12 Impact factor: 5.045
Authors: Todd T Brown; Shruti H Mehta; Catherine Sutcliffe; Yvonne Higgins; Michael S Torbenson; Richard D Moore; David L Thomas; Mark S Sulkowski Journal: AIDS Date: 2010-03-27 Impact factor: 4.177
Authors: Todd T Brown; Susheel P Patil; Lisa P Jacobson; Joseph B Margolick; Alison M Laffan; Rebecca J Godfrey; Jacquett R Johnson; Lisette M Johnson-Hill; Sandra M Reynolds; Alan R Schwartz; Philip L Smith Journal: Antivir Ther Date: 2010
Authors: Kathleen V Fitch; Lauren M Guggina; Hester M Keough; Sara E Dolan Looby; Colleen Hadigan; Ellen J Anderson; Jane Hubbard; James G Liebau; Stine Johnsen; Jeffery Wei; Hideo Makimura; Takara L Stanley; Janet Lo; Steven K Grinspoon Journal: Metabolism Date: 2009-05 Impact factor: 8.694
Authors: Todd T Brown; Xiaoqiang Xu; Majnu John; Jaya Singh; Lawrence A Kingsley; Frank J Palella; Mallory D Witt; Joseph B Margolick; Adrian S Dobs Journal: AIDS Res Ther Date: 2009-05-13 Impact factor: 2.250